ATHA Athira Gross Profit Rate

Athira Pharma, Inc. (ATHA) develops small molecules for neuron regeneration, competing in the field of combating Alzheimer's and Parkinson's diseases. Management is betting on rigorous clinical data to regain market confidence. Effective collaboration with external CRO centers ensures transparency in test monitoring. The current gross margin reflects financial stability, with the value holding at 0.00.
Financial and market metric breakdowns for athira.com (ATHA)

Athira Pharma, Inc. (ATHA) investments in a highly qualified staff of Alzheimer's researchers require significant expenditures, which directly impacts gross profit margins. This indicator is calculated as the ratio of the difference between revenue and cost of goods sold to total income, measuring production efficiency and establishing a basis for assessing the company's financial stability in the face of market risks.